The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease

Official Title

The Role of Stereo-tActic BoDy RadIotherApy iN Oligo-Progressive MalignanT Disease


Systemic therapy is the main treatment for patients with metastatic cancers. Oligo-progressionhas become a recognized entity for metastatic cancer and it is thought that a subset of cancer cells may develop heterogeneity and resistant clones while receiving systemic therapy. This results in overall tumour response but progression in metastatic sites. Current standard is to change systemic therapies. With advancing technologies, stereotactic body radiation therapy is being used to deliver high doses of focused radiation to the disease site, while minimizing risk of injury to the surrounding organs. SBRT is increasingly being used in patients presenting oligo-metastatic disease, and is recognized as having a potential for cure. This study will investigate the use of SBRT for cancer patients with oligo-progression. Patients will be seen before and at the end of treatment and will be followed at 4 month intervals for up to 2 years. During the visits participants will complete quality of life questionnaires and will have standard of care imaging. Patients will also have the option to provide blood at baseline, during treatment, and at various follow up time points for analysis of ctDNA

Trial Description

Primary Outcome:

  • Safety of SBRT in OP malignancies
  • Efficacy of SBRT in OP malignancies
  • Feasibility of SBRT in OP malignancies

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society